Fig. 2.
Fig. 2. Electrophoretic mobility shift assay. (A) Two μL of NPMS-RAR charged reticulocyte lysate (left panel) or 5 μL NPML-RAR reticulocyte lysate (right panel) was incubated with 0, 0.1, 0.2, 0.5, or 1.0 μl RXR reticulocyte lysate before incubation with radiolabeled RARβ oligonucleotide. (B) In vitro translated NPMS-RAR + RXR, NPML-RAR + RXR, or RXR alone were preincubated with 100-fold excess of cold control oligonucleotide (lane 1), cold RARβ oligonucleotide (lane 2), or no oligonucleotide (lane 3) before addition of the radiolabeled RARβ oligonucleotide. (C) 1 μg affinity purified MBP-NPMS-RAR was incubated with the radiolabeled RARβ oligonucleotide (lane 1) or preincubated with 100- (lane 2) or 1000-fold (lane 3) molar excess of unlabeled RARβ oligonucleotide before incubation with the labeled oligonucleotide.

Electrophoretic mobility shift assay. (A) Two μL of NPMS-RAR charged reticulocyte lysate (left panel) or 5 μL NPML-RAR reticulocyte lysate (right panel) was incubated with 0, 0.1, 0.2, 0.5, or 1.0 μl RXR reticulocyte lysate before incubation with radiolabeled RARβ oligonucleotide. (B) In vitro translated NPMS-RAR + RXR, NPML-RAR + RXR, or RXR alone were preincubated with 100-fold excess of cold control oligonucleotide (lane 1), cold RARβ oligonucleotide (lane 2), or no oligonucleotide (lane 3) before addition of the radiolabeled RARβ oligonucleotide. (C) 1 μg affinity purified MBP-NPMS-RAR was incubated with the radiolabeled RARβ oligonucleotide (lane 1) or preincubated with 100- (lane 2) or 1000-fold (lane 3) molar excess of unlabeled RARβ oligonucleotide before incubation with the labeled oligonucleotide.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal